Histone lysine demethylases (KDMs) are 2-oxoglutarate-dependent dioxygenases (2-OGDDs) that regulate gene expression by altering chromatin structure. Their dysregulation has been associated with many cancers. We set out to study the catalytic and inhibitory properties of human KDM4A, KDM4B, KDM5B, KDM6A and KDM6B, aiming in particular to reveal which of these enzymes are targeted by cancer-associated 2-oxoglutarate (2-OG) analogues. We used affinity-purified insect cell-produced enzymes and synthetic peptides with trimethylated lysines as substrates for the in vitro enzyme activity assays. In addition, we treated breast cancer cell-lines with cell-permeable forms of 2-OG analogues and studied their effects on the global histone methylation state. Our data show that KDMs have substrate specificity. Among the enzymes studied, KDM5B had the highest affinity for the peptide substrate but the lowest affinity for the 2-OG and the Fe 2+ cosubstrate/cofactors. R-2-hydroxyglutarate (R-2HG) was the most efficient inhibitor of KDM6A, KDM4A and KDM4B, followed by S-2HG. This finding was supported by accumulations of the histone H3K9me3 and H3K27me3 marks in cells treated with the cellpermeable forms of these compounds. KDM5B was especially resistant to inhibition by R-2HG, while citrate was the most efficient inhibitor of KDM6B. We conclude that KDM catalytic activity is susceptible to inhibition by tumorigenic 2-OG analogues and suggest that the inhibition of KDMs is involved in the disease mechanism of cancers in which these compounds accumulate, such as the isocitrate dehydrogenase mutations.
INTRODUCTION
Epigenetic modifications of the nucleic acid and protein components of chromatin are central regulators of eukaryotic transcription. These modifications include the reversible methylation of DNA and histones and further histone modifications such as acetylation, phosphorylation and ubiquitination 1 The chromatin modifications are written or erased by enzymes, with several of the erasers belonging to the family of 2-oxoglutarate-dependent dioxygenases (2-OGDDs) [1] [2] [3] [4] . The family contains ~70 enzymes in humans,
including a large number of histone lysine demethylases (KDMs), the DNA demethylases, ten-eleven translocation (TET) enzymes, the hypoxia-inducible factor prolyl 4-hydroxylases (HIF-P4Hs, also known as EglNs and PHDs) and several enzymes required for collagen biosynthesis 1, 2, 4 .
The 2-OGDDs share a common reaction mechanism, although the substrate can vary from DNA to RNA, protein, fatty acid or other small molecules 1, 2, 4 . 2-OGDDs require Fe 2+ as a cofactor and molecular oxygen and 2-oxoglutarate (2-OG, -ketoglutarate) as cosubstrates, and they yield CO2 and succinate.
Many also need a reducing agent (such as vitamin C) to retain iron in the divalent state. By coupling the sensing of cellular oxygen and 2-OG levels with that of the iron redox status, the 2-OGDDs act as central cellular metabolic sensors.
2-OG is a central intermediate of the Krebs cycle, where it is produced by isocitrate dehydrogenase
(IDH) isoenzymes 2 and 3. A 2-OG carrier mediates its efflux from mitochondria to the cytosol, where it can be used for amino acid synthesis or converted via reductive metabolism to acetyl-CoA and used for fatty acid synthesis. 2-OG can also be generated from several amino acids which can be converted to glutamate and transaminated to 2-OG. In the cytosol IDH1 provides an additional source of nonmitochondrial 2-OG.
2-OGDDs can be competitively antagonized by 2-OG analogues [1] [2] [3] [4] . These include the Krebs cycle intermediates fumarate, succinate, oxaloacetate and citrate, of which fumarate and succinate accumulate in fumarate hydratase (FH) and succinate dehydrogenase (SDH) mutant tumors, respectively [5] [6] [7] [8] . IDH
mutants that occur in certain cancers convert 2-OG to R-2-hydroxyglutarate (R-2HG), which is a 2-OG analogue oncometabolite capable of targeting 2-OGDDs [9] [10] [11] [12] [13] . Moreover, hypoxia and deficiency in the metabolizing enzyme has been shown to cause the accumulation of S-2-hydroxyglutarate (S-2HG), which can also target 2-OGDDs 14, 15 .
Histone methylation, carried out by histone methyl transferases, occurs principally on the lysyl and arginyl side chains of histones H3 and H4 1 . Up to three methyl groups can be added to a lysyl residue.
Histone demethylation is carried out by histone demethylases, of which more than 20 are KDMs 2, 3 . These are classified into two subfamilies one of which is the JmjC domain-containing KDM family that forms the largest subfamily within the 2-OGDDs. The KDMs are highly specific for the sequence surrounding the substrate lysine and the methylation status. Histone methylation can enable context-dependent activation or repression of transcription. In general, the methylation of histone H3 lysine 9 (H3K9) or H3K27, or histone H4 lysine 20 (H4K20) correlates with silent heterochromatin and transcriptional repression, whereas methylation of H3K4, H3K36 and H3K79 correlate with active euchromatin and enhanced transcription. The outcome of the methylation nevertheless depends on its site and extent, the presence of additional chromatin modifications and many other regulatory factors. KDMs play an important role in the epigenetic regulation of gene expression involved in development, cellular proliferation and differentiation, senescence and genomic stability 1 . Aberrant patterns of modification to chromatin have been associated with the onset and progression of many diseases, and recent evidence links several KDMs to the pathogenesis of a number of cancers 1, 16, 17 . Therefore many writers and erasers are pursued as small molecule targets for therapeutic benefit 3 .
Despite being high in number, the KDMs remain less well studied than the other 2-OGDDs. We therefore set out to determine the catalytic properties of several H3K4me3, H3K9me3 and H3K27me3 demethylating KDMs. We also studied the inhibitory properties of the physiologically or pathologically occurring 2-OG analogues on their activity. Finally, we used the cell-permeable forms of 2-OG analogues to study their effects on chromatin marks in cellulo.
RESULTS

Kinetic Analyses of KDMs Reveal Substrate Specificity
In order to determine the catalytic properties of the enzymes, human full-length KDM4A, KDM4B, KDM5B and KDM6A were expressed in insect cells by means of baculoviruses as FLAG or His-tagged recombinant proteins and affinity-purified using anti-FLAG or Ni-NTA chromatography. The eluted fractions were run on SDS-PAGE followed by Coomassie Blue staining (Fig. 1a) . Since a baculovirus coding for the full-length human KDM6B did not yield any soluble recombinant enzyme (data not shown), a baculovirus coding for the catalytic JmjC domain of KDM6B (aa 1164-1682) with a FLAG-tag was used instead to obtain this enzyme (Fig. 1a) .
The catalytic activities of the KDMs were analysed by a method based on measurement of the lysine demethylation-coupled stoichiometric release of 14 CO2 from 2-oxo-[1-14 C]glutarate (Fig. 1d ).
Synthetic peptides of length 19-28 residues representing histone H3 and containing a trimethylated lysine were used as substrates (Table 1 ). All the purified KDMs were active under these conditions and their activity was dependent on time ( Substrate affinity was determined first. KDM4A and KDM4B used H3K9me3 and H3K27me3 as substrates but not H3K4me3 (Fig. 2a , Table 2 , Fig.S2C-F) , the Kmvalues for these substrates being ~20-60 M ( Table 2 ). KDM5B used H3K4me3 as a substrate with a Km value of 0.8 M, but it did not demethylate the H3K9me3 or H3K27me3 substrates (Fig. 2b , Table 2 ). KDM5B also demethylated a dimethylated form of the H3K4 peptide with a Km value of 0.5 M, which was highly similar to that for the trimethylated form ( Table 2 ). For KDM6A the kcat for the longer
H3K27me3 substrate was about six-fold higher than that for the four residues shorter peptide ( Table 2 ).
The kcat/Km values for the enzymes varied from 0.016 to 0.00004 s -1 M -1 ( Table 2 ). For KDM4A no difference in the specificity between H3K9me3 and H3K27me3 substrates were detected whereas for KDM4B H3K9me3 was a more specific substrate (Table 2) . No major differences were detected in the specificity of KDM5B between the tri-and dimethylated H3K4 substrates whereas for KDM6A the longer H3K27me3 substrate was more specific than the shorter one ( Table 2 ). Among H3K27me3 demethylating enzymes KDM6A had the highest specificity for this substrate ( Table 2 ).
The Km values of the enzymes studied for the 2-OG cosubstrate were 6-50 µM, KDM4B having the highest affinity and KDM6B the lowest (Fig. 2d , e, Table 3 , Fig. S3 ). These values were similar to those of HIF-P4H-1, FIH and TET2, which are other 2-OGDDs operating in the nucleus (Table 3 ) 8, 19, 20 . The Km values of the other enzymes studied here for iron (<0.1 µM) were lower than that of KDM6B, which was 6 µM (Fig. 2f , Table 3 ) and thus similar to that of TET2 21 .
KDMs Are Susceptible to Inhibition by 2-OG Analogues
We next studied the inhibition of KDMs by the cancer-associated 2-OG analogues fumarate, succinate, R-2HG and S-2HG and the metabolic regulators citrate and oxaloacetate. All the recombinant KDM enzymes studied were susceptible to competitive inhibition by succinate, R-2HG, S-2HG, citrate and Table 4 , Figs. S5-9). Fumarate was only a weak inhibitor of KDM4A and KDM6A, with IC50 values of 2300 and 3000 µM (Fig. S4A, B) , respectively, and did not inhibit KDM4B, KDM5B or KDM6B (Table 4 ). The oncometabolite R-2HG appeared to be the most potent inhibitor of KDM4A, KDM4B and KDM6A among the 2-OG analogues studied, with IC50 values of <200 µM ( Fig.   3a , Table 4 , Fig. S5A, D) , and R-2HG was also the second most potent inhibitor of KDM6B, with an IC50
value of 350 µM ( Table 4 , Fig. S5E ). Unlike the other KDMs studied, R-2HG was only a very weak inhibitor of KDM5B, with an IC50 value of 3600 µM, which was also the case with its S-enantiomer (Table 4 (Table 4 , Fig. S8 ). It was also the most potent inhibitor of KDM5B among the 2-OG analogues studied, with an IC50 value of 800 µM ( Table 4 , Fig. S8C ). The IC50 values of all the KDMs studied for oxaloacetate were 380-900 M (Table 4 , Fig. S9 ), which was the smallest variation among the IC50 values of the KDMs studied here for any of the 2-OG analogues.
Treatment of Breast Cancer Cells with Cell-Permeable 2-OG Analogues Increases Global H3K27 and H3K9 Methylation Levels
To evaluate the potential of the cancer-associated 2-OG analogues to inhibit KDMs in cellulo, we treated three subtypes of breast cancer cells, BT474 (ER+, HER2+), SK-BR-3 (ER-, HER2+) and MCF7 (ER+, HER2-) with cell-permeable forms of fumarate (DEF), succinate (DMS), R-2HG (TFMB-R-2HG) and S-2HG (TFMB-S-2HG), the cells being exposed to increasing concentrations of these for 72 h. DMSO-treated cells were used as controls. These compounds have been earlier reported to increase intracellular concentrations of fumarate, succinate, R-2HG and S-2HG 8, 20, 22 . Changes in global histone methylation with respect to H3K9 and H3K27, the marks demethylated by KDM4A, KDM4B, KDM6A and KDM6B, which were the most susceptible to inhibition by 2-OG analogues (Table 4) , were determined by immunoblotting. HIF-1 stabilization was also assessed in SK-BR-3 and MCF7 cells. Fumarate, R-2HG
and S-2HG significantly increased both H3K27me3 and H3K9me3 levels in all three cell lines (Fig. 4) , but the increases were more modest in the SK-BR-3 cells than in the BT474 and MCF7 cells (Fig. 4) .
Succinate slightly increased H3K27me3 and H3K9me3 levels in the BT474 and SK-BR-3 cells but these changes were modest by comparison with the other compounds (Fig. 4a, b) . The most prominent effect of succinate was seen on H3K9me3 levels in the BT474 cells (Fig. 4a ). R-2HG and S-2HG treatment showed dose-dependent increases in H3K27me3 and H3K9me3 levels in all the cell lines studied (Fig. 4) .
Fumarate, succinate, R-2HG and S-2HG stabilized HIF1 in SK-BR-3 and MCF7 cells (Fig. S10) .
Altogether, these data show that increased intracellular 2-OG analogue concentrations can lead to increased H3K27 and H3K9 methylation. The differences in sensitivity observed in the different cells likely stem from differences in the endogenous expression levels of histone demethylases and methyltransferases, and the differences in the genomic background of the cells.
DISCUSSION
We report here on the catalytic and inhibitory properties of the high molecular weight full-length insect cell affinity-purified human enzymes KDM4A, KDM4B, KDM5B and KDM6A and the JmjC domain of KDM6B using the same assay detecting demethylation-coupled 2-OG decarboxylation in all cases. This setting provides a basis for comparing the results between the enzymes and for gaining an understanding of which enzymes are actually inhibited by the 2-OG-analogue oncometabolites and are causally linked to the transformed phenotype. Previous reports have concentrated on kinetic and inhibitory data for the catalytic domains of human KDM4A and KDM5B and full-length KDM5B, these data having been generated by methods that detect substrate demethylation by MALDI-TOF-MS or antibody-based AlphaScreen or formaldehyde dehydrogenase (FDH) assay, which detects formaldehyde generated by substrate hydroxylation and subsequent demethylation 2, 18, [23] [24] [25] [26] [27] [28] [29] . Of the available methods MALDI-TOF-MS is the only direct method available to detect the demethylated product. The AlphaScreen technology relies on the product-recognizing antibodies. Therefore any unspecificity in them is a weakness of this method. Although being indirect the formaldehyde detected in the FDH assay stems directly from the hydoxylated product. This assay measures continuous formation of formaldehyde, unlike the others that measure product at end point. The substrate demethylation-coupled 2-OG decarboxylation assay used here measures 14 C-labeled CO2 derived from the 14 C-labeled 2-OG providing high specificity and sensitivity. As the 2-OGDDs can catalyse to a small extent uncoupled decarboxylation of 2-OG negative control reactions where the peptide substrate is omitted must be performed in parallel with ones containing the substrate. The benefit of the indirect assays compared with direct ones is that the one assay can be used for all enzymes that use the same reaction method. For example, the AlphaScreen requires a specific antibody for all products.
Our data show that the catalytic properties among the studies KDMs are highly similar, yet there are specificities among the enzymes. KDM4A and KDM4B demethylated peptides with trimethylated lysines in positions 9 and 27 in histone H3, while the other enzymes studied were specific for a single substrate. The former is in agreement with a previous observation, but our data do not suggest any difference in the affinity of the peptides representing the two demethylation sites in histone H3 for tested a longer peptide that included these amino acids as a substrate 31 and found that its Km value was lower, 130 M. It was nevertheless still the highest among the enzymes studied here, however, its kcat value for the longer peptide was highly similar if not identical with KDM6B. Altogether, these data suggest that the assay used, the substrate length and the catalyst length (full-length vs. catalytic domain) may affect the kinetic values obtained for KDMs. As the KDMs can also demethylate dimethylated lysines, and in some cases even monomethylated ones, the product of an assay using a trimethylated peptide as a substrate may serve as a substrate for a second catalytic reaction 2, 30 . Also, the affinities for differently methylated substrates may vary, adding further complexity to the interpretation of the results.
The affinities for 2-OG and iron were highly similar for all the KDMs studied except for KDM6B, which had a >3-fold higher Km value for 2-OG and a >60-fold higher value for Fe 2+ than any other enzyme. Such findings would suggest that when these reactants become limiting, KDM6B activity is the first to decline. Among the nuclear 2-OGDDs, the kinetics of KDM6B resembled those of TET2, whereas HIF-P4H-1 and FIH possess values that are more similar to those for the other KDMs ( M for iron was much larger than that of the HIF-P4Hs 19 that regulate HIF stability, this could be expected to be of some physiological relevance.
Somatic mutations in IDH1 and IDH2 identified in gliomas, acute myeloid leukaemia, chondrosarcoma and cholangiosarcoma, and less commonly in bladder cancer, for example, lead to the accumulation of R-2HG at millimolar levels [9] [10] [11] [33] [34] [35] . Among the 2-OG analogues studied here, R-2HG
was the most potent antagonist of KDM4A, KDM4B, KDM6A and KDM6B, suggesting that the oncogenesis promoted by R-2HG involved inhibition of histone demethylation and especially accumulation of H3K27me3 and H3K9me3. This is in agreement with the reported accumulation of these marks in IDH1/2 mutant glial tumors 36 . Treatment of breast cancer cells with cell-permeable R-2HG resulted in concentration dependent-accumulation of the H3K27me3 and H3K9me3 marks, suggesting that R-2HG can also efficiently target the enzymes modifying these markers in cellulo. R-2HG was a more potent or equally potent inhibitor of the KDMs studied here than was S-2HG for which levels up to 300 M haven been reported in hypoxic mammalian cells 37 and 750 M in S-2HG dehydrogenase mutant patients 38 . This is contrary to our earlier report for other 2-OGDDs such as FIH, TET1/2, collagen prolyl 4-hydroxylase and HIF-P4Hs, for which S-2HG was always a more efficient inhibitor than R-2HG 13 . For the HIF-P4Hs, R-2HG is actually not an inhibitor at all but can act as a weak alternative cosubstrate instead of 2-OG 13 . These data suggest potential structural differences in the binding pocket for 2-OG or its competitive analogues between KDMs and other 2-OGDDs.
Succinate, which can accumulate up to millimolar levels in SDH mutant paragangliomas 5, 7 , was a moderately potent inhibitor of KDM6A and KDM6B, which is in agreement with the reported accumulation of the H3K27me3 mark in SDH mutant paragangliomas and pheochromocytomas 39 .
Treatment of breast cancer cells with cell-permeable succinate nevertheless only resulted in minor increases in the H3K27me3 marks, a higher accumulation of H3K9me3 being detected in one cell line.
These observations may suggest cell-type specific differences in the epigenetic marks mediated by succinate. Among the 2-OG analogues studied here, fumarate, which accumulates up to millimolar levels in FH-mutant renal cancers in particular 6, 7 Altogether, these data suggest that fumarate may mediate its effects in these histone marks indirectly and in a manner independent of KDM inhibition.
Surprisingly, citrate, a central regulator of lipid and glucose metabolism, appeared to be a very potent inhibitor of KDM6B and a moderate inhibitor of KDM6A. Elevated plasma citrate levels up to 160
M have been reported associated e.g. with non-alcohol fatty liver disease 40 . Interestingly, KDM6A
activation and H3K27me3 demethylation have been associated with brown adipocyte thermogenetic programming, which is a mechanism by which rodents combat obesity 41 . Moreover, ATP-citrate lyase, an enzyme that converts citrate to acetyl-CoA, is required for another modification, histone acetylation 42 . It has also been reported recently that chronic exposure of the heart to R-2HG, which causes contractile dysfunction, contributed to increased intracellular citrate concentration and modifications to the cardiac epigenome 43 . Oxaloacetate, a central regulator of several key biosynthetic pathways, such as gluconeogenesis and the synthesis of several essential amino acids, was a moderate inhibitor of KDM4A, KDM6A and KDM6B and its IC50 values did not exceed the millimolar level for any of the KDMs studied. Altogether, these data may provide an understanding of the mechanisms by which environmental factors such as diet can influence epigenetic regulation.
Although genetic alterations in KDMs have been identified in various human cancers, the precise role of KDMs in tumorigenesis remains unclear 1, 16, 17 . In some cancers the alterations lead to downregulation of the corresponding enzyme and in others to upregulation. Of the KDMs studied here, inactivating mutations have mainly been reported for KDM6A in lung, liver, esophageal, renal and bladder cancer, multiple myeloma and leukaemia, while KDM5B expression has been reported to be amplified in prostate, breast and bladder cancer 44 . Our inhibitory data support these disease mechanisms in that the catalytic activity of KDM6A, unlike that of KDM5B, was significantly more susceptible to inhibition by 2-OG-analogue oncometabolites. The tumor suppressor role of KDM6A has been further supported by its ability to prevent epithelial to mesenchymal transition in breast cancer stem cells 45 . For KDM4A both activating and inactivating mutations have been reported, in breast cancer and bladder cancer, respectively, while for KDM4B and KDM6B only activating mutations have been found 44 . The association of upregulation of KDM4A, KDM4B, KDM5B and KDM6B with certain cancers has made them targets for developing inhibitors to treat these diseases 3 . Our present data shed light on the mechanism behind the increased histone methylation levels observed in many cancers that involve FH, SDH and IDH mutations, but they also support the concept that it should be possible to develop specific inhibitors for the various KDMs, as they possess catalytic properties that vary from one another and are distinct from those of other 2-OGDD.
MATERIALS AND METHODS
Expression and Purification of Recombinant Enzymes
The baculoviruses for human full-length KDM5B and KDM6A with C-terminal FLAG tags were a gift from Dr. Qin Yan. cDNA clones for human full-length KDM4A and KDM4B in the pReceiver-I01 plasmid were a gift from Dr. Susanne Schlisio, and the corresponding baculoviruses with N-terminal Histags were generated. The baculoviral construct for human KDM6B 1164-1682 (coding for the catalytic JmjC domain) was amplified by PCR using the corresponding cDNA as a template. The C-terminal FLAG tag was generated by PCR and the constructs were cloned into the pVL1393 backbone. The corresponding baculovirus was generated using the BacMagic-3 DNA kit (Novagen). The baculoviruses were used to express recombinant proteins in Sf9 insect cells in TNM-FH media supplemented with 10% fetal bovine serum. The cells were infected with the respective baculoviruses and harvested 72 h after infection, washed with PBS, and homogenized in a buffer containing 10 mM Tris-HCl (pH 7.8), 150 mM NaCl, µmM glycine, 5 µM FeSO4, 0.1% Triton X-100 and EDTA-free protease inhibitor (Roche).
Soluble fractions of the FLAG-tagged enzymes were purified with an anti-FLAG M2 affinity gel (Sigma).
For His-tagged KDM4A and KDM4B, the soluble fractions were affinity purified using Ni-NTA agarose (Qiagen) and eluted with imidazole, which was then removed with PD-10 columns (Sigma). The fractions collected were analysed using 8% SDS-PAGE under reducing conditions followed by Coomassie Blue staining.
Kinetic Activity Assays
The catalytic activities of the KDM enzymes were determined using an assay in which the stoichiometric lysine demethylation-coupled decarboxylation of 2-OG to CO2 was detected. The assay was modified from one used to determine the catalytic activities of several 2-OGDDs values were determined from the saturation curves using Excel (Microsoft).
Cell Culture Experiments with Cell-Permeable Fumarate, Succinate, R-2HG and S-2HG
Diethyl fumarate (DEF) (Sigma) and dimethyl succinate (DMS) (Sigma) were purchased. Trifluoromethyl benzyl (TFMB)-esterified R-2-hydroxyglutarate (TFMB-R-2HG) and TFMB-S-2HG were synthesized as described before 22 . BT474 and SK-BR-3 cells were maintained in RPMI 1640 medium (Sigma). MCF7 
